These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 12548584

  • 21. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 22. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 23. Bisphosphonates: clinical experience.
    Coleman RE.
    Oncologist; 2004 Feb; 9 Suppl 4():14-27. PubMed ID: 15459426
    [Abstract] [Full Text] [Related]

  • 24. Mechanisms of osteolytic bone metastases in breast carcinoma.
    Käkönen SM, Mundy GR.
    Cancer; 2003 Feb 01; 97(3 Suppl):834-9. PubMed ID: 12548583
    [Abstract] [Full Text] [Related]

  • 25. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
    Tanaka T, Kawashima H, Ohnishi K, Matsumura K, Yoshimura R, Matsuyama M, Kuratsukuri K, Nakatani T.
    Anticancer Res; 2009 Apr 01; 29(4):1089-94. PubMed ID: 19414350
    [Abstract] [Full Text] [Related]

  • 26. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.
    Clézardin P, Ebetino FH, Fournier PG.
    Cancer Res; 2005 Jun 15; 65(12):4971-4. PubMed ID: 15958534
    [Abstract] [Full Text] [Related]

  • 27. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
    Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT.
    Cancer Res; 2002 May 01; 62(9):2708-14. PubMed ID: 11980672
    [Abstract] [Full Text] [Related]

  • 28. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.
    Mönkkönen J, Taskinen M, Auriola SO, Urtti A.
    J Drug Target; 1994 May 01; 2(4):299-308. PubMed ID: 7858955
    [Abstract] [Full Text] [Related]

  • 29. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep 01; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 30. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC.
    Cancer Res; 2000 Nov 01; 60(21):6001-7. PubMed ID: 11085520
    [Abstract] [Full Text] [Related]

  • 31. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
    Mitrofan LM, Pelkonen J, Mönkkönen J.
    Bone; 2009 Dec 01; 45(6):1153-60. PubMed ID: 19699819
    [Abstract] [Full Text] [Related]

  • 32. Bisphosphonates: new therapeutic agents for the treatment of bone tumors.
    Heymann D, Ory B, Gouin F, Green JR, Rédini F.
    Trends Mol Med; 2004 Jul 01; 10(7):337-43. PubMed ID: 15242682
    [Abstract] [Full Text] [Related]

  • 33. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
    Plotkin LI, Manolagas SC, Bellido T.
    Bone; 2006 Sep 01; 39(3):443-52. PubMed ID: 16627025
    [Abstract] [Full Text] [Related]

  • 34. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG, Rogers MJ.
    Bone; 1999 Jul 01; 25(1):97-106. PubMed ID: 10423031
    [Abstract] [Full Text] [Related]

  • 35. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.
    Bone; 2011 Jul 01; 49(1):20-33. PubMed ID: 21497677
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T, Kawasoe Y, Yamashita Y, Ueno Y, Minami S, Yokouchi M, Komiya S.
    Anticancer Res; 2008 Jul 01; 28(4B):2147-54. PubMed ID: 18751388
    [Abstract] [Full Text] [Related]

  • 37. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O, Tiedemann K, Komarova SV.
    Bone; 2011 Feb 01; 48(2):202-11. PubMed ID: 20849994
    [Abstract] [Full Text] [Related]

  • 38. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
    Conte P, Guarneri V.
    Oncologist; 2004 Feb 01; 9 Suppl 4():28-37. PubMed ID: 15459427
    [Abstract] [Full Text] [Related]

  • 39. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I, Kousidou OCh, Karamanos NK.
    In Vivo; 2005 Feb 01; 19(1):311-8. PubMed ID: 15796191
    [Abstract] [Full Text] [Related]

  • 40. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.
    Ann N Y Acad Sci; 2007 Nov 01; 1117():209-57. PubMed ID: 18056045
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.